Skip to main content

Table 4 Pharmacokinetic parameters of camrelizumab following a single dose

From: Safety, activity, and pharmacokinetics of camrelizumab in advanced Asian melanoma patients: a phase I study

Parameters (CV%)

60 mg (n = 12)

200 mg (n = 12)

400 mg (n = 12)

Cmax (ug/ml) mean ± SD, (%CV)

19.93 ± 4.21 (21.1)

73.93 ± 11.09 (15.0)

139.69 ± 23.49 (16.8)

Tmax (hours), median (range)

0.73 (0.63, 48.42)

0.71 (0.65, 24.65)

0.78 (0.65, 6.72)

AUC0-t (day·ug/ml), median (%CV)

68.77 (38.8)

400.69 (22.5)

1044.37 (18.9)

AUC0-inf (day·ug/ml), median (%CV)

68.46 (39.2)

452.31 (27.8)

1285.45 (23.6)

t1/2, day, median (%CV)

3.06 (31.1)

5.92 (27.8)

12.22 (25.8)

Rac,cmax, median (%CV)

1.11 (21.4)

1.50 (7.3)

1.37 (10.3)

  1. SD Standard deviation, CV Coefficient of variation, Cmax Maximal plasma concentration, Tmax Time to maximal plasma concentration, AUC0-t Area under the concentration-time curve from 0 to the last measurable concentration, AUC0-inf Area under the concentration-time curve from 0 to infinite time; t½ terminal half-life, Rac,cmax The accumulation ratio calculated by Cmax